PP
REGN icon

Pacifica Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Pacifica Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Hold
20
– – ﹤0.01% 287
2026
Q1 		$15.5K Hold
20
– – 0.01% 278
2025
Q4 		$15.5K Buy
20
+10
+100% +$6.79K 0.01% 265
2025
Q3 		$6K Hold
10
– – ﹤0.01% 375
2025
Q2 		$5.21K Hold
10
– – ﹤0.01% 392
2025
Q1 		$6.11K Hold
10
– – ﹤0.01% 373
2024
Q4 		$7.15K Buy
+10
New +$8.39K ﹤0.01% 352

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Pacifica Partners's REGN Position: Q2 2026 in Review

Pacifica Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 20 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #287.

Pacifica Partners first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $15.5K in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Pacifica Partners held 20 shares of Regeneron Pharmaceuticals worth $13.1K as of Q2 2026.
  • Pacifica Partners left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Pacifica Partners's portfolio in Q2 2026, its #287 holding.
  • Pacifica Partners first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Pacifica Partners's Regeneron Pharmaceuticals position peaked at $15.5K in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Pacifica Partners's 13F filing for Q2 2026, filed 13 Jul 2026.